Imita Science Co., Ltd. (CEO Tae Seok-ho) announced that it will participate in ‘BIO KOREA 5’ held at COEX, Seoul for three days from May 10 (Wed) to 12 (Fri).
Imita Science provides a screening platform for effective substance efficacy, toxicity evaluation and new drug development based on biomimetic organ-on-a-chip technology, and furthermore, it dramatically replaces the non-clinical stage of animal testing. The ultimate goal is to grow into a non-clinical CRO company that entrusts toxicity and pharmacological evaluations through biomimetic organ chips that mimic human organs.
The biomimetic organ chip operation equipment for research to be introduced at this exhibition is an operation equipment for precise fluid flow control, and is used for research and analysis together with the developed biomimetic organ chip for research. In the case of the PDMS biomimetic multi-organ chip, microfluidic technology is applied, and effective non-clinical tests are possible through multi-organ interaction.
In addition, the PE material organ chip upgraded from the existing PDMS biomimetic multi-organ chip can be used as a user-customized screening kit. Artificial fatty liver disease modeling through cell culture in a biomimetic multi-organ chip The organ chip is used for the validation of a specific substance and can be used for the development of effective substances through low-cost and high-efficiency tests compared to existing animal tests. In the case of a skin tissue organ chip in which blood vessels are simulated through vascular cell culture, unlike existing non-clinical experiments on skin tissue, it is possible to derive results closer to actual clinical results with a structure similar to that of the human body.
An official from Imita Science said, “We provide new solutions to researchers based on organ chip technology. By pioneering non-clinical CRO and diagnostic fields with organ-on-a-chip technology, an alternative to animal testing, we are solving the ethical and cost problems of animal testing and increasing the similarity with actual clinical test results.”
“Through the user-customized design of the PE material multi-organ biomimetic chip, we plan to distribute screening kits to each place of use. In addition, we plan to research and develop disease modeling chips, and also plan to research and develop female genital disease modeling chips through collaboration with Ewha Womans University Mokdong Hospital.”
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.